{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:35:34Z","timestamp":1770752134889,"version":"3.50.0"},"reference-count":60,"publisher":"Journal of Biomedical Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2023]]},"DOI":"10.7555\/jbr.36.20220052","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:03:07Z","timestamp":1669284187000},"page":"194","source":"Crossref","is-referenced-by-count":5,"title":["Antitumor efficacy of multi-target &lt;i&gt;in situ&lt;\/i&gt; vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers"],"prefix":"10.7555","volume":"37","author":[{"given":"Anastasia S.","family":"Proskurina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera S.","family":"Ruzanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genrikh S.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav R.","family":"Efremov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakhar S.","family":"Mustafin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey A.","family":"Lashin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina A.","family":"Burakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alesya A.","family":"Fokina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timofei S.","family":"Zatsepin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry A.","family":"Stetsenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Y.","family":"Leplina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandr A.","family":"Ostanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena R.","family":"Chernykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey S.","family":"Bogachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4380","reference":[{"key":"key-10.7555\/JBR.36.20220052-1","doi-asserted-by":"publisher","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al.  Cancer statistics for the year 2020: an overview[J]. <i>Int J Cancer, <\/i>2021, 149(4): 778\u2013789.","DOI":"10.1002\/ijc.33588"},{"key":"key-10.7555\/JBR.36.20220052-2","doi-asserted-by":"publisher","unstructured":"Mellman I, Coukos G, Dranoff G.  Cancer immunotherapy comes of age[J]. <i>Nature, <\/i>2011, 480(7378): 480\u2013489.","DOI":"10.1038\/nature10673"},{"key":"key-10.7555\/JBR.36.20220052-3","doi-asserted-by":"publisher","unstructured":"Makkouk A, Weiner GJ.  Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge[J]. <i>Cancer Res, <\/i>2015, 75(1): 5\u201310.","DOI":"10.1158\/0008-5472.CAN-14-2538"},{"key":"key-10.7555\/JBR.36.20220052-4","doi-asserted-by":"crossref","unstructured":"Vinay DS, Ryan EP, Pawelec G, et al.  Immune evasion in cancer: mechanistic basis and therapeutic strategies[J]. <i>Semin Cancer Biol, <\/i>2015, 35 Suppl 1: S185\u2013S198.","DOI":"10.1016\/j.semcancer.2015.03.004"},{"key":"key-10.7555\/JBR.36.20220052-5","doi-asserted-by":"crossref","unstructured":"Mittal D, Gubin MM, Schreiber RD, et al.  New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape[J]. <i>Curr Opin Immunol, <\/i>2014, 27(1): 16\u201325.","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"key-10.7555\/JBR.36.20220052-6","doi-asserted-by":"publisher","unstructured":"Wang J, Xu Y, Huang Z, et al.  T cell exhaustion in cancer: mechanisms and clinical implications[J]. <i>J Cell Biochem, <\/i>2018, 119(6): 4279\u20134286.","DOI":"10.1002\/jcb.26645"},{"key":"key-10.7555\/JBR.36.20220052-7","doi-asserted-by":"publisher","unstructured":"Dine J, Gordon R, Shames Y, et al.  Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer[J]. <i>Asia Pac J Oncol Nurs, <\/i>2017, 4(2): 127\u2013135.","DOI":"10.4103\/apjon.apjon_4_17"},{"key":"key-10.7555\/JBR.36.20220052-8","doi-asserted-by":"publisher","unstructured":"Alizadeh D, Larmonier N.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells[J]. <i>Cancer Res, <\/i>2014, 74(10): 2663\u20132668.","DOI":"10.1158\/0008-5472.CAN-14-0301"},{"key":"key-10.7555\/JBR.36.20220052-9","doi-asserted-by":"publisher","unstructured":"Shirota Y, Shirota H, Klinman DM.  Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells[J]. <i>J Immunol, <\/i>2012, 188(4): 1592\u20131599.","DOI":"10.4049\/jimmunol.1101304"},{"key":"key-10.7555\/JBR.36.20220052-10","doi-asserted-by":"publisher","unstructured":"Marabelle A, Tselikas L, de Baere T, et al.  Intratumoral immunotherapy: using the tumor as the remedy[J]. <i>Ann Oncol, <\/i>2017, 28(S12): xii33\u2013xii43.","DOI":"10.1093\/annonc\/mdx683"},{"key":"key-10.7555\/JBR.36.20220052-11","doi-asserted-by":"publisher","unstructured":"Sagiv-Barfi I, Lu H, Hewitt J, et al.  Intratumoral injection of TLR4 agonist (G100) leads to tumor regression of A20 lymphoma and induces abscopal responses[J]. <i>Blood, <\/i>2015, 126(23): 820.","DOI":"10.1182\/blood.V126.23.820.820"},{"key":"key-10.7555\/JBR.36.20220052-12","doi-asserted-by":"publisher","unstructured":"Sagiv-Barfi I, Czerwinski DK, Levy S, et al.  Eradication of spontaneous malignancy by local immunotherapy[J]. <i>Sci Transl Med, <\/i>2018, 10(426): eaan4488.","DOI":"10.1126\/scitranslmed.aan4488"},{"key":"key-10.7555\/JBR.36.20220052-13","doi-asserted-by":"publisher","unstructured":"Mildner A, Jung S.  Development and function of dendritic cell subsets[J]. <i>Immunity, <\/i>2014, 40(5): 642\u2013656.","DOI":"10.1016\/j.immuni.2014.04.016"},{"key":"key-10.7555\/JBR.36.20220052-14","doi-asserted-by":"publisher","unstructured":"Gardner A, Ruffell B.  Dendritic cells and cancer immunity[J]. <i>Trends Immunol, <\/i>2016, 37(12): 855\u2013865.","DOI":"10.1016\/j.it.2016.09.006"},{"key":"key-10.7555\/JBR.36.20220052-15","doi-asserted-by":"publisher","unstructured":"Bayik D, Tross D, Klinman DM.  Factors influencing the differentiation of human monocytic myeloid-derived suppressor cells into inflammatory macrophages[J]. <i>Front Immunol, <\/i>2018, 9: 608.","DOI":"10.3389\/fimmu.2018.00608"},{"key":"key-10.7555\/JBR.36.20220052-16","doi-asserted-by":"crossref","unstructured":"Tyrinova TV, Leplina OY, Mishinov SV, et al.  Cytotoxic activity of <i>ex-vivo<\/i> generated IFN\u03b1-induced monocyte-derived dendritic cells in brain glioma patients[J]. <i>Cell Immunol, <\/i>2013, 284(1-2): 146\u2013153.","DOI":"10.1016\/j.cellimm.2013.07.013"},{"key":"key-10.7555\/JBR.36.20220052-17","doi-asserted-by":"publisher","unstructured":"Zong JB, Keskinov AA, Shurin GV, et al.  Tumor-derived factors modulating dendritic cell function[J]. <i>Cancer Immunol Immunother, <\/i>2016, 65(7): 821\u2013833.","DOI":"10.1007\/s00262-016-1820-y"},{"key":"key-10.7555\/JBR.36.20220052-18","doi-asserted-by":"publisher","unstructured":"Behboudi S, Chao D, Klenerman P, et al.  The effects of DNA containing CpG motif on dendritic cells[J]. <i>Immunology, <\/i>2000, 99(3): 361\u2013366.","DOI":"10.1046\/j.1365-2567.2000.00979.x"},{"key":"key-10.7555\/JBR.36.20220052-19","doi-asserted-by":"publisher","unstructured":"Scheiermann J, Klinman DM.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer[J]. <i>Vaccine, <\/i>2014, 32(48): 6377\u20136389.","DOI":"10.1016\/j.vaccine.2014.06.065"},{"key":"key-10.7555\/JBR.36.20220052-20","doi-asserted-by":"publisher","unstructured":"Shirota H, Klinman DM.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant[J]. <i>Expert Rev Vaccines, <\/i>2014, 13(2): 299\u2013312.","DOI":"10.1586\/14760584.2014.863715"},{"key":"key-10.7555\/JBR.36.20220052-21","doi-asserted-by":"publisher","unstructured":"Shirota H, Tross D, Klinman DM.  CpG oligonucleotides as cancer vaccine adjuvants[J]. <i>Vaccines, <\/i>2015, 3(2): 390\u2013407.","DOI":"10.3390\/vaccines3020390"},{"key":"key-10.7555\/JBR.36.20220052-22","doi-asserted-by":"publisher","unstructured":"Krug A, Towarowski A, Britsch S, et al.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12[J]. <i>Eur J Immunol, <\/i>2001, 31(10): 3026\u20133037.","DOI":"10.1002\/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H"},{"key":"key-10.7555\/JBR.36.20220052-23","doi-asserted-by":"publisher","unstructured":"Hoene V, Peiser M, Wanner R.  Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19[J]. <i>J Leukoc Biol, <\/i>2006, 80(6): 1328\u20131336.","DOI":"10.1189\/jlb.0106011"},{"key":"key-10.7555\/JBR.36.20220052-24","doi-asserted-by":"publisher","unstructured":"Zhu M, Xu W, Su H, et al.  Addition of CpG ODN and Poly (I: C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity[J]. <i>Hum Vaccin Immunother, <\/i>2015, 11(7): 1596\u20131605.","DOI":"10.1080\/21645515.2015.1046659"},{"key":"key-10.7555\/JBR.36.20220052-25","doi-asserted-by":"publisher","unstructured":"Krug A, Rothenfusser S, Selinger S, et al.  CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells[J]. <i>J Immunol, <\/i>2003, 170(7): 3468\u20133477.","DOI":"10.4049\/jimmunol.170.7.3468"},{"key":"key-10.7555\/JBR.36.20220052-26","doi-asserted-by":"publisher","unstructured":"Croft M.  Control of immunity by the TNFR-related molecule OX40 (CD134)[J]. <i>Ann Rev Immunol, <\/i>2010, 28(1): 57\u201378.","DOI":"10.1146\/annurev-immunol-030409-101243"},{"key":"key-10.7555\/JBR.36.20220052-27","doi-asserted-by":"publisher","unstructured":"Piconese S, Valzasina B, Colombo MP.  OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection[J]. <i>J Exp Med, <\/i>2008, 205(4): 825\u2013839.","DOI":"10.1084\/jem.20071341"},{"key":"key-10.7555\/JBR.36.20220052-28","doi-asserted-by":"publisher","unstructured":"Gough MJ, Ruby CE, Redmond WL, et al.  OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor[J]. <i>Cancer Res, <\/i>2008, 68(13): 5206\u20135215.","DOI":"10.1158\/0008-5472.CAN-07-6484"},{"key":"key-10.7555\/JBR.36.20220052-29","doi-asserted-by":"publisher","unstructured":"Kitamura N, Murata S, Ueki T, et al.  OX40 costimulation can abrogate Foxp3<sup>+<\/sup> regulatory T cell-mediated suppression of antitumor immunity[J]. <i>Int J Cancer, <\/i>2009, 125(3): 630\u2013638.","DOI":"10.1002\/ijc.24435"},{"key":"key-10.7555\/JBR.36.20220052-30","doi-asserted-by":"publisher","unstructured":"Curti BD, Kovacsovics-Bankowski M, Morris N, et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients[J]. <i>Cancer Res, <\/i>2013, 73(24): 7189\u20137198.","DOI":"10.1158\/0008-5472.CAN-12-4174"},{"key":"key-10.7555\/JBR.36.20220052-31","doi-asserted-by":"publisher","unstructured":"Redmond WL, Weinberg AD.  Targeting OX40 and OX40L for the treatment of autoimmunity and cancer[J]. <i>Crit Rev Immunol, <\/i>2007, 27(5): 415\u2013436.","DOI":"10.1615\/CritRevImmunol.v27.i5.20"},{"key":"key-10.7555\/JBR.36.20220052-32","doi-asserted-by":"publisher","unstructured":"Aspeslagh S, Postel-Vinay S, Rusakiewicz S, et al.  Rationale for anti-OX40 cancer immunotherapy[J]. <i>Eur J Cancer, <\/i>2016, 52: 50\u201366.","DOI":"10.1016\/j.ejca.2015.08.021"},{"key":"key-10.7555\/JBR.36.20220052-33","doi-asserted-by":"publisher","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. <i>Eur J Cancer, <\/i>2016, 54: 139\u2013148.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"key-10.7555\/JBR.36.20220052-34","doi-asserted-by":"publisher","unstructured":"Thommen DS, Schumacher TN.  T cell dysfunction in cancer[J]. <i>Cancer Cell, <\/i>2018, 33(4): 547\u2013562.","DOI":"10.1016\/j.ccell.2018.03.012"},{"key":"key-10.7555\/JBR.36.20220052-35","doi-asserted-by":"publisher","unstructured":"Pardoll DM.  The blockade of immune checkpoints in cancer immunotherapy[J]. <i>Nat Rev Cancer, <\/i>2012, 12(4): 252\u2013264.","DOI":"10.1038\/nrc3239"},{"key":"key-10.7555\/JBR.36.20220052-36","doi-asserted-by":"publisher","unstructured":"Merelli B, Massi D, Cattaneo L, et al.  Targeting the PD1\/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities[J]. <i>Crit Rev Oncol Hematol, <\/i>2014, 89(1): 140\u2013165.","DOI":"10.1016\/j.critrevonc.2013.08.002"},{"key":"key-10.7555\/JBR.36.20220052-37","doi-asserted-by":"publisher","unstructured":"Ross K, Jones RJ.  Immune checkpoint inhibitors in renal cell carcinoma[J]. <i>Clin Sci, <\/i>2017, 131(21): 2627\u20132642.","DOI":"10.1042\/CS20160894"},{"key":"key-10.7555\/JBR.36.20220052-38","doi-asserted-by":"publisher","unstructured":"Ott PA, Hodi FS, Robert C.  CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients[J]. <i>Clin Cancer Res, <\/i>2013, 19(19): 5300\u20135309.","DOI":"10.1158\/1078-0432.CCR-13-0143"},{"key":"key-10.7555\/JBR.36.20220052-39","doi-asserted-by":"publisher","unstructured":"Scott AM, Wolchok JD, Old LJ.  Antibody therapy of cancer[J]. <i>Nat Rev Cancer, <\/i>2012, 12(4): 278\u2013287.","DOI":"10.1038\/nrc3236"},{"key":"key-10.7555\/JBR.36.20220052-40","doi-asserted-by":"publisher","unstructured":"Melero I, Hervas-Stubbs S, Glennie M, et al.  Immunostimulatory monoclonal antibodies for cancer therapy[J]. <i>Nat Rev Cancer, <\/i>2007, 7(2): 95\u2013106.","DOI":"10.1038\/nrc2051"},{"key":"key-10.7555\/JBR.36.20220052-41","doi-asserted-by":"publisher","unstructured":"Dillman RO.  Cancer immunotherapy[J]. <i>Cancer Biother Radiopharm, <\/i>2011, 26(1): 1\u201364.","DOI":"10.1089\/cbr.2010.0902"},{"key":"key-10.7555\/JBR.36.20220052-42","doi-asserted-by":"publisher","unstructured":"Mahoney KM, Freeman GJ, McDermott DF.  The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma[J]. <i>Clin Ther, <\/i>2015, 37(4): 764\u2013782.","DOI":"10.1016\/j.clinthera.2015.02.018"},{"key":"key-10.7555\/JBR.36.20220052-43","doi-asserted-by":"publisher","unstructured":"Niezgoda A, Niezgoda P, Czajkowski R.  Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy[J]. <i>Biomed Res Int, <\/i>2015, 2015: 851387.","DOI":"10.1155\/2015\/851387"},{"key":"key-10.7555\/JBR.36.20220052-44","doi-asserted-by":"publisher","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J]. <i>Nat Rev Clin Oncol, <\/i>2019, 16(9): 563\u2013580.","DOI":"10.1038\/s41571-019-0218-0"},{"key":"key-10.7555\/JBR.36.20220052-45","doi-asserted-by":"publisher","unstructured":"Adachi T, Nakamura Y.  Aptamers: a review of their chemical properties and modifications for therapeutic application[J]. <i>Molecules, <\/i>2019, 24(23): 4229.","DOI":"10.3390\/molecules24234229"},{"key":"key-10.7555\/JBR.36.20220052-46","doi-asserted-by":"publisher","unstructured":"Radko SP, Rakhmetova SY, Bodoev NV, et al.  Aptamers as affinity reagents for clinical proteomics[J]. <i>Biochem (Moscow) Suppl Ser B:Biomed Chem, <\/i>2007, 1(3): 198\u2013209.","DOI":"10.1134\/S1990750807030043"},{"key":"key-10.7555\/JBR.36.20220052-47","doi-asserted-by":"publisher","unstructured":"Bom APDA, da Costa Neves PC, de Almeida CEB, et al.  Aptamers as delivery agents of siRNA and chimeric formulations for the treatment of cancer[J]. <i>Pharmaceutics, <\/i>2019, 11(12): 684.","DOI":"10.3390\/pharmaceutics11120684"},{"key":"key-10.7555\/JBR.36.20220052-48","doi-asserted-by":"publisher","unstructured":"Nozari A, Berezovski MV.  Aptamers for CD antigens: from cell profiling to activity modulation[J]. <i>Mol Ther Nucleic Acids, <\/i>2017, 6: 29\u201344.","DOI":"10.1016\/j.omtn.2016.12.002"},{"key":"key-10.7555\/JBR.36.20220052-49","doi-asserted-by":"publisher","unstructured":"Nimjee SM, Rusconi CP, Sullenger BA.  Aptamers: an emerging class of therapeutics[J]. <i>Annu Rev Med, <\/i>2005, 56: 555\u2013583.","DOI":"10.1146\/annurev.med.56.062904.144915"},{"key":"key-10.7555\/JBR.36.20220052-50","doi-asserted-by":"publisher","unstructured":"Zhou J, Li H, Li S, et al.  Novel dual inhibitory function aptamer\u2013siRNA delivery system for HIV-1 therapy[J]. <i>Mol Ther, <\/i>2008, 16(8): 1481\u20131489.","DOI":"10.1038\/mt.2008.92"},{"key":"key-10.7555\/JBR.36.20220052-51","unstructured":"Santulli-Marotto S, Nair SK, Rusconi C, et al.  Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity[J]. <i>Cancer Res, <\/i>2003, 63(21): 7483\u20137489."},{"key":"key-10.7555\/JBR.36.20220052-52","doi-asserted-by":"publisher","unstructured":"Miroshnichenko SK, Patutina OA, Burakova EA, et al.  Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties[J]. <i>Proc Natl Acad Sci U S A, <\/i>2019, 116(4): 1229\u20131234.","DOI":"10.1073\/pnas.1813376116"},{"key":"key-10.7555\/JBR.36.20220052-53","doi-asserted-by":"publisher","unstructured":"Prakash TP, Mullick AE, Lee RG, et al.  Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle[J]. <i>Nucleic Acids Res, <\/i>2019, 47(12): 6029\u20136044.","DOI":"10.1093\/nar\/gkz354"},{"key":"key-10.7555\/JBR.36.20220052-54","doi-asserted-by":"publisher","unstructured":"Pratico ED, Sullenger BA, Nair SK.  Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40[J]. <i>Nucleic Acid Ther, <\/i>2013, 23(1): 35\u201343.","DOI":"10.1089\/nat.2012.0388"},{"key":"key-10.7555\/JBR.36.20220052-55","doi-asserted-by":"publisher","unstructured":"Dollins CM, Nair S, Boczkowski D, et al.  Assembling OX40 Aptamers on a molecular scaffold to create a receptor-activating aptamer[J]. <i>Chem Biol, <\/i>2008, 15(7): 675\u2013682.","DOI":"10.1016\/j.chembiol.2008.05.016"},{"key":"key-10.7555\/JBR.36.20220052-56","doi-asserted-by":"publisher","unstructured":"Prodeus A, Abdul-Wahid A, Fischer NW, et al.  Targeting the PD-1\/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers[J]. <i>Mol Ther Nucleic Acids, <\/i>2015, 4: e237.","DOI":"10.1038\/mtna.2015.11"},{"key":"key-10.7555\/JBR.36.20220052-57","doi-asserted-by":"publisher","unstructured":"Ostanin AA, Leplina OY, Burakova EA, et al.  Phosphate-modified CpG oligonucleotides induce in vitro maturation of human myeloid dendritic cells[J]. <i>Vavilovskii Zhurnal Genet Selektsii (in Russian), <\/i>2020, 24(6): 653\u2013660.","DOI":"10.18699\/VJ20.659"},{"key":"key-10.7555\/JBR.36.20220052-58","doi-asserted-by":"publisher","unstructured":"Ruzanova VS, Proskurina AS, Ritter GS, et al.  Experimental comparison of the <i>in vivo<\/i> efficacy of two novel anticancer therapies[J]. <i>Anticancer Res, <\/i>2021, 41(7): 3371\u20133387.","DOI":"10.21873\/anticanres.15125"},{"key":"key-10.7555\/JBR.36.20220052-59","doi-asserted-by":"publisher","unstructured":"Lai W, Huang BT, Wang J, et al.  A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects[J]. <i>Mol Ther Nucleic Acids, <\/i>2016, 5: e397.","DOI":"10.1038\/mtna.2016.102"},{"key":"key-10.7555\/JBR.36.20220052-60","doi-asserted-by":"publisher","unstructured":"Hammond SM, Sergeeva OV, Melnikov PA, et al.  Mesyl phosphoramidate oligonucleotides as potential splice-switching agents: impact of backbone structure on activity and intracellular localization[J]. <i>Nucleic Acid Ther, <\/i>2021, 31(3): 190\u2013200.","DOI":"10.1089\/nat.2020.0860"}],"container-title":["The Journal of Biomedical Research"],"original-title":[],"link":[{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.36.20220052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T08:49:18Z","timestamp":1684918158000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.36.20220052?viewType=HTML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"alternative-id":["JBR-2022-0052"],"URL":"https:\/\/doi.org\/10.7555\/jbr.36.20220052","relation":{},"ISSN":["1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}